Successful rechallenge of alectinib after remission of severe alectinib-induced interstitial lung disease.

ola Kala shared this article with you from Inoreader Successful rechallenge of alectinib after remission of severe alectinib-induced interstitial lung disease. Μέσω pubmed: "j oncol pharm pract... Successful rechallenge of alectinib after remission of severe alectinib-induced interstitial lung disease. J Oncol Pharm Pract. 2020 Oct 14;:1078155220961557 Authors: Huang JR, Chou CW, Chao HS Abstract INTRODUCTION: Even though alectinib is a potent second-generation ALK inhibitor with a favorable safety profile, alectinib-induced interstitial lung disease (ILD) could be fatal. There are case reports described successful alectinib rechallenge in mild ILD. However, the feasibility and safety of rechallenge in severe cases remains to be elucidated. CASE REPORT: A 76-year-old female was a case of stage IV lung adenocarcinoma harboring ALK rearrangement. Respiratory failure following severe ILD developed one month after alectinib administration. She received mechanical ventilation in intensive care uint. ILD subsided gradually after methylprednisolone pulse therapy and discontinuation of alectinib.Management and outcome: After the recovery from ILD, the patient attempted a re-escalation of alectinib from a lower dose under close clinical and radiological monitoring. No ILD happened even after 480 days of alectinib rechallenge. DISCUSSION: Given that the ALK inhibitors are the treatment of choice for advanced lung cancer patients with ALK rearrangement. Our report demonstrated the potential feasibility of alectinib re-use in cases of severe druginduced ILD. PMID: 33054691 [PubMed - as supplied by publisher] View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.